Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Osbond acid, also known as n-6 docosapentaenoic acid (DPA), is a long-chain polyunsaturated omega-6 fatty acid (22:5n-6). It is synthesized endogenously from arachidonic acid via elongation to adrenic acid followed by further desaturation and elongation steps. In human health and nutrition, osbond acid is most significant as a biochemical marker for docosahexaenoic acid (DHA) status; because the same enzymes (delta-6 desaturase) are used to synthesize both DHA and osbond acid, the body increases osbond acid production when DHA levels are insufficient. Consequently, an elevated DHA-to-osbond acid ratio is often used to distinguish healthy dietary patterns from those deficient in omega-3 fatty acids. Research has investigated its associations with cognitive function, mood disorders like depression, and cardiometabolic risk factors, particularly in maternal and neonatal health.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on osbond acid.